9995 — RemeGen Co Income Statement
0.000.00%
Last trade - 00:00
- HK$8.67bn
- HK$10.34bn
- CNY1.08bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.82 | 3.04 | 1,426 | 772 | 1,083 |
Cost of Revenue | |||||
Gross Profit | 1.39 | 0.737 | 1,358 | 500 | 826 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 435 | 707 | 1,124 | 1,767 | 2,584 |
Operating Profit | -430 | -704 | 303 | -995 | -1,502 |
Gain / Loss on Sale of Assets | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -430 | -698 | 276 | -999 | -1,511 |
Net Income After Taxes | -430 | -698 | 276 | -999 | -1,511 |
Net Income Before Extraordinary Items | |||||
Net Income | -430 | -698 | 276 | -999 | -1,511 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -430 | -698 | 276 | -999 | -1,511 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.79 | -1.28 | 0.513 | -1.88 | -2.8 |
Dividends per Share |